GT199700115A - Agentes nicotinicos en terapia. - Google Patents

Agentes nicotinicos en terapia.

Info

Publication number
GT199700115A
GT199700115A GT199700115A GT199700115A GT199700115A GT 199700115 A GT199700115 A GT 199700115A GT 199700115 A GT199700115 A GT 199700115A GT 199700115 A GT199700115 A GT 199700115A GT 199700115 A GT199700115 A GT 199700115A
Authority
GT
Guatemala
Prior art keywords
compounds
therapy
nicotinic agents
nicotinic
agents
Prior art date
Application number
GT199700115A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT199700115A publication Critical patent/GT199700115A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A LOS COMPUESTOS DE AZABICICLICOS. MAS CONCRETAMENTE SE REFIERE COMPUESTOS AZABICICLICOS CONDENSADOS CON PIRIDONA, ESTOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE TRASTORNOS DE ADICCION, TALES COMO EL USO DEL TABACO O DE OTROS PRODUCTOS QUE CONTIENEN NICOTINA. ESTOS COMPUESTOS TIENEN LA ESTRUCTURA QUIMICA ( I ), EN LA QUE R1, R2 Y R3 SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE.
GT199700115A 1996-10-30 1997-10-27 Agentes nicotinicos en terapia. GT199700115A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2880496P 1996-10-30 1996-10-30

Publications (1)

Publication Number Publication Date
GT199700115A true GT199700115A (es) 1999-04-20

Family

ID=21845528

Family Applications (1)

Application Number Title Priority Date Filing Date
GT199700115A GT199700115A (es) 1996-10-30 1997-10-27 Agentes nicotinicos en terapia.

Country Status (17)

Country Link
US (2) US6235734B1 (es)
EP (1) EP0937077B1 (es)
JP (2) JP3621707B2 (es)
AP (1) AP9701125A0 (es)
AR (1) AR008901A1 (es)
AT (1) ATE326468T1 (es)
AU (1) AU4394897A (es)
DE (1) DE69735891T2 (es)
ES (1) ES2264169T3 (es)
GT (1) GT199700115A (es)
HR (1) HRP970567A2 (es)
ID (1) ID18741A (es)
MA (1) MA26445A1 (es)
PA (1) PA8440201A1 (es)
TN (1) TNSN97168A1 (es)
WO (1) WO1998018798A1 (es)
ZA (1) ZA979706B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6717030B2 (en) * 1998-07-06 2004-04-06 The Regents Of The University Of California Protein kinase C epsilon as modulator of anxiety, alcohol consumption and self-administration of drugs of abuse
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US20010036943A1 (en) * 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
US20020010192A1 (en) * 2000-06-02 2002-01-24 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20020016334A1 (en) * 2000-07-31 2002-02-07 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
PL369886A1 (en) 2001-11-30 2005-05-02 Pfizer Products Inc. Aryl fused azapolycyclic compounds
SE0104463D0 (sv) * 2001-12-29 2001-12-29 Carlbiotech Ltd As Mellanprodukter för syntes af LHRH-antagonister, sätt att framställa dem och sätt för framställning av LHRH-antagonister
US20030162770A1 (en) 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20040224963A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US8030300B2 (en) 2003-06-10 2011-10-04 Georgetown University Ligands for nicotinic acetylcholine receptors, and methods of making and using them
DE602004023299D1 (de) 2003-07-21 2009-11-05 Pfizer Prod Inc Nikotin abhängigkeit reduzierende heteroaryl kondensierte azapolycyclische verbindungen
US20050234024A1 (en) * 2004-04-14 2005-10-20 Clarke David E Materials and methods for the treatment of ulcerative colitis
US7135933B2 (en) * 2004-09-29 2006-11-14 Intelliserv, Inc. System for adjusting frequency of electrical output pulses derived from an oscillator
ATE395348T1 (de) * 2004-12-07 2008-05-15 Pfizer Prod Inc 1,2,3,3a;8,8a-hexahydro-2,7a- diazacyclopenta(a)inden-7-onderivate, die sich an neuronale nikotinische acetylcholinspezifische rezeptorstellen binden und zur modulation der cholinergen funktion und zur behandlung von suchterkrankungen eignen
US20060211649A1 (en) * 2005-03-21 2006-09-21 Eric Marchewitz Use of cytisine for enhancing physical performance
US20070134169A1 (en) * 2005-12-11 2007-06-14 Rabinoff Michael D Methods for smoking cessation or alcohol cessation or other addiction cessation
WO2007100430A2 (en) * 2006-01-27 2007-09-07 Yale University Cytisine and acetylcholine analogs and methods of treating mood disorders
WO2007115092A2 (en) * 2006-03-29 2007-10-11 Georgetown University 10-substituted cytisine derivatives and methods of use thereof
US7404725B2 (en) * 2006-07-03 2008-07-29 Hall David R Wiper for tool string direct electrical connection
US8061443B2 (en) * 2008-04-24 2011-11-22 Schlumberger Technology Corporation Downhole sample rate system
MX339842B (es) 2009-12-22 2016-06-14 Avon Prod Inc Composiciones estimuladoras de paxilina y usos cosmeticos de las mismas.
US20110159125A1 (en) 2009-12-29 2011-06-30 Avon Products, Inc. CGRP Compositions and Uses Thereof
FR2992315B1 (fr) * 2012-06-25 2014-08-08 Pf Medicament Derives utiles dans le traitement de maladies du systeme nerveux central
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN102952134B (zh) * 2012-12-05 2015-01-07 苏州药明康德检测检验有限责任公司 含二氟甲基的金雀花碱衍生物及制备方法和抗癌作用研究
RU2630958C2 (ru) * 2015-12-29 2017-09-15 федеральное государственное автономное образовательное учреждение высшего образования "Московский физико-технический институт (государственный университет)" (МФТИ) Новые макроциклические соединения, содержащие природное 3,7-диазабицикло[3.3.1]нонановое ядро и способ их получения
GB201602145D0 (en) 2016-02-05 2016-03-23 Achieve Pharma Uk Ltd Salt
HUE061016T2 (hu) 2016-08-19 2023-05-28 Univ Bristol Citizin-származékok a szenvedélybetegségek kezelésére
US11459328B2 (en) 2017-07-24 2022-10-04 Achieve Pharma Uk Limited Cytisine salts
CA3153405A1 (en) * 2019-09-12 2021-03-18 Achieve Life Sciences, Inc. Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59500217A (ja) 1982-02-22 1984-02-16 ベロルススキ−　ナウチノ−　イスレドワ−チエルスキ−　サニタルノ−　ギギエニチエスキ−　インスチツ−ト 抗ニコチン効果を有する製剤およびその製造法
US4835162A (en) 1987-02-12 1989-05-30 Abood Leo G Agonists and antagonists to nicotine as smoking deterents
US5242916A (en) * 1992-07-07 1993-09-07 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
TW261531B (es) 1993-10-28 1995-11-01 Dynagen Inc
AU7083596A (en) * 1995-09-22 1997-04-09 Novo Nordisk A/S Novel substituted azacyclic or azabicyclic compounds

Also Published As

Publication number Publication date
JP3621707B2 (ja) 2005-02-16
ATE326468T1 (de) 2006-06-15
JP2005060403A (ja) 2005-03-10
US6630467B2 (en) 2003-10-07
EP0937077A1 (en) 1999-08-25
WO1998018798A1 (en) 1998-05-07
HRP970567A2 (en) 1998-10-31
ES2264169T3 (es) 2006-12-16
AU4394897A (en) 1998-05-22
TNSN97168A1 (fr) 2005-03-15
US20030065173A1 (en) 2003-04-03
ID18741A (id) 1998-05-07
MA26445A1 (fr) 2004-12-20
ZA979706B (en) 1999-04-29
AP9701125A0 (en) 1997-10-31
AR008901A1 (es) 2000-02-23
DE69735891T2 (de) 2006-12-14
DE69735891D1 (de) 2006-06-22
JP2000505809A (ja) 2000-05-16
PA8440201A1 (es) 2000-05-24
US6235734B1 (en) 2001-05-22
EP0937077B1 (en) 2006-05-17

Similar Documents

Publication Publication Date Title
GT199700115A (es) Agentes nicotinicos en terapia.
GT199700079A (es) Derivados triciclos sustituidos con fenilamino
CR9879A (es) Moduladores de ccr5 (divisional de la solicitud n° 6392)
ATE207897T1 (de) Piperidinderivate als neurokininantagonisten
GT199700089A (es) Derivados 6.6 o 6.7 -biciclicos sustituidos que contienen pirido o pirimido.
DK0817770T3 (da) Nonpeptider som tachykininantagonister
GT199700141A (es) Prevencion de la perdida y restauracion de la masa osea por determinados agonistas de prostaglandinas.
HN1999000080A (es) Derivados de isotiazol utiles como agentes anticancerosos.
BG104247A (en) Resorcinol derivatives
ES2167592T3 (es) Preparaciones medicamentosas que contienen un enantiomero de bromuro de ipratropio con duracion de la accion prolongada.
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
ES2189235T3 (es) 6-fenilfenantridinas sustituidas.
PT934309E (pt) Novas piridil-alcano-amidas como agentes citostaticos e imunossupressivos
GT199900067A (es) Nuevas 4-fenilpiperidinas para el tratamiento dedermatosis prurìtica.
GT199800032A (es) 2-amino-6-(4-fenoxi-2-sustituido)-piridinas sustituidas.
CU23241B7 (es) 2-fenil-1-(4(2-aminoetoxi)-benzil)-indol en combinacion con estrogenos
GT199800083A (es) Agonistas de prostaglandinas.
CY1111396T1 (el) Ρινικη χορηγηση μετοκλοπραμιδης για την αγωγη της γαστροπαρεσης
GT199800106A (es) Azetidinas.
ES2194222T3 (es) Dispositivo para la administracion asistida electricamente de agentes tales como lidocaina y epinefrina.
GT199800135A (es) 2 - aminopiridinas con sustituyentes alcoxi ramificados.
ES2167356T3 (es) Utilizacion de tioureilenos y tiabendazol en enfermedades autoinmunitarias e inflamatorias de la piel.
UY26877A1 (es) Compuestos pirazol-tiazol, composiciones farmacéuticas que los contienen, y su modo de empleo para inhibir quinasas ciclino- dependientes
AR030788A1 (es) Antagonistas de receptores de taquiquinina zwitterionica
ECSP034530A (es) Derivados de 6-metil-tramadol sustituido en o